Antimicrobial Treatment and Management of Central Nervous System Infections

Message from the Guest Editors

The central nervous system (CNS) might be considered a sanctuary for infections. Transport of fluid and solutes is tightly controlled within the CNS, as the entry of drugs into the cerebrospinal fluid (CSF) is governed by molecular size, lipophilicity, plasma protein binding and their affinity to transport systems at the blood–brain barrier (BBB).

In the literature, only a few papers are available regarding therapeutic regimens for hospital-acquired (HA) CNS infections, especially in terms of requiring antibiotics combinations or therapy duration. In the absence of updated guidelines, there is little experience in the use of novel antibiotics in difficult-to-treat pathogens which are increasingly responsible for nosocomial infections in Neurosurgery Departments.

This Special Issue seeks manuscript submissions that deepen our understanding of the treatment and management of CNS infections and broaden our knowledge in this challenging field, in particular regarding HA Infections. Submissions regarding pharmacokinetic studies of novel antibiotics in HA CNS infections are especially encouraged.
Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics )

Contact Us

*Antibiotics* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
www.mdpi.com
antibiotics@mdpi.com
X@antibioticsmdpi